Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;13(6):1239-1244.
doi: 10.1007/s41999-022-00706-5. Epub 2022 Nov 29.

Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee

Affiliations

Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee

Peggy M Cawthon et al. Eur Geriatr Med. 2022 Dec.

Abstract

Methods: The aim of this paper is to define terms commonly related to sarcopenia to enable standardization of these terms in research and clinical settings. The Global Leadership Initiative in Sarcopenia (GLIS) aims to bring together leading investigators in sarcopenia research to develop a single definition that can be utilized worldwide; work on a global definition of sarcopenia is ongoing. The first step of GLIS is to develop the common terminology, or a glossary, that will facilitate agreement on a global definition of sarcopenia as well as interpretation of clinical and research findings.

Results: Several terms that are commonly used in sarcopenia research are defined, including self-reported measures of function and ability; objective physical performance tests; and measures related to muscle function and size.

Conclusion: As new methods and technologies are developed, these definitions may be expanded or refined over time. Our goal is to promote this common language to describe sarcopenia and its components in clinical and research settings in order to increase clinical awareness and research interest in this important condition. We hope that the use of common terminology in sarcopenia research will increase understanding of the concept and improve communication around this important age-related condition.

Keywords: GLIS; Sarcopenia; Standardization; Terminology.

PubMed Disclaimer

Conflict of interest statement

Dr. Cruz-Jentoft reports obtaining research funding from AstraZeneca. Dr. Kirk reports consultancy/honorarium fees from the following companies/enterprises that work in the medical and/or musculoskeletal fields: Abbott Nutrition (UK); Academy of Nutrition and Dietetics (USA); AusDoc (Australian Doctor). Dr. Kirk is also supported by a research grant from TSI Pharmaceuticals. Dr. Kiel reports royalties from publication Wolters Kluwer for chapters in UpToDate on Falls; scientific advisory boards for Pfizer, Solarea Bio, Reneo; grants from Amgen and Solarea Bio; Data Safety and Safety Monitoring Board for Agnovos. Dr. Landi reports consultancy and invited lecture to Abbott, Nutricia, ErreKappa, and Professional Dietetics. Dr. Duque reports paid consultancy for TSI, Abbott, and Nutricia. Dr. Bruyère reports to being a shareholder of SARQOL SRL. Dr. Cawthon reports being a consultant to BioAge Labs. Dr. Fielding reports to being a paid consultant for Pfizer, Nestle, Amazentis, Biophytis, Rejuvenate Biomed, Juvicell. Dr. Fielding reports to being on the advisory Board for Inside Tracker and Cytokinetics and reports to being a shareholder of Azcella Health. He has obtained research funding from Lonza. Dr. Bhasin reports consultancy fees from OPKO Health and Aditum Bio. He has obtained research funding from AbbVie and Metro International BioTech. Dr. Von Haehling reports being a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Chugai, Grünenthal, Helsinn, Hexal, Novartis, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor. Dr. Cederholm reports providing paid lectures arranged by medical nutrition companies. Dr. Binder reports consulting income from Eisai, Inc. Drs. Sayer, Cooper, Arai, Guralnik, Woo, Ávila-Funes, Chen, Visser, Barazzoni report no current personal financial interests.

References

    1. Evans WJ, Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr. 1993;123(2 Suppl):465–468. doi: 10.1093/jn/123.suppl_2.465. - DOI - PubMed
    1. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–763. doi: 10.1093/oxfordjournals.aje.a009520. - DOI - PubMed
    1. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–256. doi: 10.1016/j.jamda.2011.01.003. - DOI - PMC - PubMed
    1. Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–558. doi: 10.1093/gerona/glu010. - DOI - PMC - PubMed
    1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing. 2010;39(4):412–423. doi: 10.1093/ageing/afq034. - DOI - PMC - PubMed